Evidence map›Paper›PMID 31632472›Full record

ReviewTherapeutic advances in musculoskeletal disease2019

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis.

Salvatore Minisola, Cristiana Cipriani, Giada Della Grotta, Luciano Colangelo, Marco Occhiuto, Piergianni Biondi, Chiara Sonato, Evelina Vigna, Mirella Cilli, Jessica Pepe

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in musculoskeletal disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Osteoprotective effect ofPharmaceutical biology · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. PTHrP promotes subchondral bone formation in TMJ-OA.International journal of oral science · 2022
    Article
  19. Therapeutic peptides: current applications and future directions.Signal transduction and targeted therapy · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Salvatore MinisolaDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Viale del Policlinico, 155, Rome, 00161, Italy.ORCID https://orcid.org/0000-0001-6525-0439
Cristiana CiprianiDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Giada Della GrottaDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Luciano ColangeloDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Marco OcchiutoDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Piergianni BiondiDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Chiara SonatoDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Evelina VignaDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Mirella CilliDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Jessica PepeDepartment of Internal Medicine and Medical Disciplines, "Sapienza" Rome University, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the completion of the Fracture Prevention Trial, teriparatide was approved by the United States Food and Drug Administration and the European Medicine Agency as the first therapeutic anabolic agent for the treatment of postmenopausal women with severe osteoporosis. It subsequently received additional approval for the treatment of osteoporosis in men, and for the treatment of osteoporosis associated with glucocorticoid therapy in men and women at risk of fracture. In this review, we summarize the most important data concerning PTH 1-34 therapy before 2016 in the treatment of osteoporosis, and report some outstanding results published in the last 2 years. New data on safety will also discussed, together with the state of art of nonclassical utilization. Finally, in view of the recent approval of biosimilars, possible future landscapes are discussed.

Indexed as

fracturesosteoporosissafetyteriparatide

Identifiers

PMID31632472
PMCPMC6778993
OpenAlexW2978676553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.